Rectal Cancer 5-Year Survival Rate: What Does It Look Like Going Into 2026?

Rectal cancer is reported together with colon cancer in Korea's national statistics. The combined 5-year relative survival rate for colorectal cancer in Korea is 75.6% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea). Note, however, that this figure combines colon and rectal cancer together, and any individual's actual prognosis depends on stage and overall health.

Key Takeaways

• Korea's 5-year relative survival rate for colorectal cancer (combining colon and rectal cancer) is 75.6%, based on National Cancer Registration Statistics for 2019–2023 (National Cancer Center Korea).
• In the United States, the SEER 5-year relative survival rate for colorectal cancer (2016–2022) is 65.4%. Both figures are nationwide statistics, not results from any specific hospital.
• A substantial part of the gap is attributed to differences in early-detection rates. Korea's national screening program offers an annual fecal occult blood test starting at age 50, with a positive result leading to a follow-up colonoscopy.
• Colorectal Cancer Notes does not provide a survival figure broken out for rectal cancer alone; statistics are only available for colon and rectal cancer combined as 'colorectal cancer.'
• Survival rates are population averages. An individual's actual outcome can vary considerably depending on stage, age, and overall health.

Is There a Separate Survival Rate Just for Rectal Cancer?

• No separately published figure exists. National cancer registration statistics combine colon and rectal cancer into a single 'colorectal cancer' category with a 5-year relative survival rate of 75.6%, so there is no basis for presenting a rectal-cancer-only figure.
• That said, rectal cancer requires surgery within the confined space of the pelvis, and when the tumor has deeply invaded the bowel wall or spread to lymph nodes, standard practice now often involves pre-surgical (neoadjuvant) radiation and chemotherapy before resection. This approach aims to shrink the tumor and improve the chances of preserving the anus.
• Colon cancer is usually resected laparoscopically, and for stage III disease or stage II with risk factors, several months of postoperative adjuvant chemotherapy follows surgery.
• In other words, even within the same 'colorectal cancer' statistics, the treatment course and expected outcome can differ substantially depending on whether the cancer is in the colon or rectum, and what stage it is.

Why Does Korea's Survival Rate Appear Higher Than the U.S.'s?

• It's important to note that both figures (75.6% in Korea, 65.4% in the U.S.) represent nationwide statistics, not the treatment outcomes of any particular hospital.
• Much of the difference stems from the timing of detection. Korea's national screening system provides an annual fecal occult blood test starting at age 50, with follow-up colonoscopy for positive results — a system that tends to catch more cases at the polyp stage or early cancer stage.
• Colorectal cancer is well understood to progress through a long-growing polyp that eventually becomes cancerous, meaning that removing polyps via colonoscopy can itself serve as prevention.
• These kinds of national-level screening system differences cannot be directly translated into an individual's personal prognosis.

How Do Treatment and Outcomes Differ by Stage?

• Colorectal cancer is staged using the TNM system. Stages 0–1 are confined to the mucosa or a shallow layer with no lymph node involvement; stage 2 has deeply invaded the bowel wall but without lymph node spread; stage 3 involves lymph node metastasis; and stage 4 has spread to distant organs such as the liver or lungs.
• Early-stage colorectal cancer can often be treated with colonoscopic resection alone (endoscopic mucosal resection or endoscopic submucosal dissection), meaning no bowel is actually removed.
• Even in stage 4, if the metastatic sites (such as liver or lung lesions) can be surgically removed, treatment combining chemotherapy with metastasis resection may be pursued with curative intent — meaning colorectal cancer tends to have a wider range of treatment options at stage 4 compared with many other cancers.
• Immunotherapy is known to be particularly effective in cases confirmed as MSI-High. For advanced or metastatic disease, drug selection is guided by biomarker testing results including MSI/MMR, RAS, BRAF, and HER2.

FAQ — If I Have Rectal Cancer, Can I Avoid a Colostomy (Stoma)?

This depends on the tumor's location, its distance from the anus, and how well it responds to pre-surgical chemotherapy and radiation. Pelvic MRI review can help estimate in advance whether anal preservation is feasible, and if preoperative treatment shrinks the tumor sufficiently, anus-preserving surgery may become possible. A temporary stoma that is later reversed after several months is also a commonly used approach.

FAQ — How Is Follow-Up Monitoring Done After Treatment?

After treatment ends, patients undergo regular clinical exams and CEA blood tests at set intervals, along with chest and abdominal CT scans to check for recurrence in the liver or lungs. Colonoscopy is typically performed once around one year after surgery, with the interval extended afterward depending on results. Monitoring tends to be more frequent during the first 2–3 years and continues through year 5. The specific schedule varies depending on stage and treatment received.

Sources and Notes

• This article was written based on National Cancer Registration Statistics 2019–2023 (National Cancer Center Korea), SEER 2016–2022 data, and patient-level guidance from the National Cancer Information Center and NCCN-level colorectal cancer resources (Colorectal Cancer Notes).
• This content is intended for general medical information purposes only. Diagnosis, treatment approach, and outcomes may vary depending on an individual's condition. Please consult with a medical professional to determine an accurate diagnosis and appropriate treatment.